Advertisement
NKTX vs VIR
Which Stock Would AI Choose? Nkarta (NKTX) vs. Vir Biotechnology (VIR) Stock Comparison
Key Takeaways
- NKTX is a clinical-stage developer of off-the-shelf natural killer (NK) cell therapies, while VIR spans infectious diseases and oncology with a late-stage hepatitis delta program and a masked T-cell engager pipeline.
- Relative momentum diverges sharply: VIR has roughly doubled year-to-date and trades near 52-week highs, whereas NKTX has trended lower and sits near the bottom of its 52-week range.
- Both carry "Strong Buy" consensus ratings, but VIR pairs positive momentum with a stronger balance sheet and near-term clinical catalysts.
- VIR delivered a pivotal Phase 3 success in chronic hepatitis delta, while NKTX is earlier-stage and awaits key autoimmune data readouts.
- Tickeron AI Verdict: Based on trend consistency, catalysts, and relative positioning, the AI favors VIR over NKTX in the current market environment.
- For deeper context, explore NKTX Major News, NKTX Today's Price Move, VIR Major News, and VIR Today's Price Move.
- To see how algorithmic strategies are navigating these and other names, visit the curated Trending AI Robots page.
Introduction
Both NKTX and VIR are clinical-stage biotechnology companies, yet they currently occupy very different positions in the market. NKTX (Nkarta) is an early-stage developer of engineered natural killer (NK) cell therapies, while VIR (Vir Biotechnology) has advanced late-stage infectious-disease programs alongside an emerging oncology platform. This stock comparison is most relevant for growth-oriented investors and traders weighing relative performance, clinical catalysts, and balance-sheet strength. Because the two names have moved in opposite directions over recent months, they offer a useful contrast in how market positioning, momentum, and binary clinical events shape sentiment in the biotech sector.
NKTX Overview and Recent Performance
NKTX, or Nkarta, develops allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its lead candidate, NKX019, is a CD19-directed chimeric antigen receptor NK (CAR-NK) therapy being studied primarily in autoimmune diseases, while NKX101 targets cells displaying NKG2D ligands. The company has a market capitalization of roughly $200 million and remains pre-revenue, funding operations through equity raises and a cash runway that extends several years out.
Recent stock behavior has been weak relative to the broader biotech tape. Shares have traded near the lower end of their 52-week range after declining significantly from earlier highs, reflecting investor caution around execution risk and competition in cell therapy. That said, the name has shown intermittent strength on regulatory and clinical milestones—for example, rallying on news of U.S. Food and Drug Administration (FDA) protocol amendments and an agreement around outpatient dosing. Analyst sentiment remains constructive, with a "Strong Buy" consensus and price targets well above current levels, but the stock's trend has yet to confirm that optimism. Sentiment is best described as contrarian: the valuation is depressed, but near-term catalysts are weighted toward future data readouts.
VIR Overview and Recent Performance
VIR, or Vir Biotechnology, develops medicines for serious infectious diseases and cancer. Its most advanced program combines elebsiran and tobevibart for chronic hepatitis delta (CHD), the most severe form of chronic viral hepatitis. The company also advances a portfolio of PRO-XTEN dual-masked T-cell engagers (TCEs), including VIR-5500 (PSMA-targeted, partnered with Astellas), VIR-5818 (HER2), and VIR-5525 (EGFR).
Recent market activity has been markedly positive. The pivotal Phase 3 ECLIPSE 1 trial met all primary and key secondary endpoints, and expanded Phase 2 SOLSTICE data suggested durable viral suppression—news that sent shares sharply higher and toward 52-week highs. The stock has roughly doubled on the year, supported by a narrower-than-expected quarterly loss, a "Strong Buy" consensus rating, and a series of analyst price-target increases. The balance sheet is also a differentiator: VIR ended its latest quarter with more than $900 million in cash and investments, excluding an upfront payment from a newly announced Gilead research collaboration. That financial cushion, combined with FDA Breakthrough Therapy and Fast Track designations, has underpinned a more favorable risk-reward narrative than its smaller peer.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance profile, and target universe. Because market conditions are constantly shifting, not every bot is equally suited to the current environment—so Tickeron curates only the strongest, most relevant strategies into its Trending AI Robots section. This shortlist highlights the bots whose recent statistics and alignment with present market conditions stand out, giving traders a focused starting point rather than an overwhelming catalog. Whether you are evaluating names like NKTX and VIR or scanning the broader market, exploring the Trending AI Robots can help you identify data-driven approaches that fit your objectives.
Head-to-Head Comparison
The two companies differ most in stage, momentum, and financial footing. VIR is further along the development curve, with a late-stage asset that has already produced positive pivotal data and a regulatory filing targeted for mid-2027. Its oncology pipeline adds optionality and is externally validated through collaborations with Astellas and Gilead. NKTX, by contrast, is an earlier-stage platform play concentrated in cell therapy, where competition is intensifying and key efficacy data are still pending.
From a momentum standpoint, the contrast is stark. VIR is in a confirmed uptrend, trading above key moving averages and near its high, while NKTX has yet to establish durable upward momentum and carries a higher beta, implying greater volatility. On risk factors, NKTX faces clinical and competitive risk concentrated in a single therapeutic modality, whereas VIR spreads risk across infectious disease and multiple oncology programs. Balance-sheet strength also favors VIR, whose cash position funds operations into the second half of 2028, offering more runway than NKTX relative to its burn rate. The trade-off is valuation: NKTX trades at a fraction of analyst price targets, offering larger potential upside but with materially higher uncertainty.
Tickeron AI Verdict
On observable factors—trend consistency, momentum, the presence of near-term catalysts, balance-sheet strength, and the breadth of the pipeline—Tickeron's AI would currently lean toward VIR over NKTX. The combination of a positive pivotal trial, a confirmed uptrend, a sizable cash buffer, and multiple partnered programs gives VIR a more stable and diversified positioning at present. NKTX retains meaningful upside potential and strong analyst support, but its trend has not yet aligned with that optimism, and its catalysts are more distant. This verdict is probabilistic rather than definitive, reflecting conditions that can shift as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NKTX is a Hold and VIR is a Hold.
NKTX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NKTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 66 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on November 04, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 208 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.500) is normal, around the industry mean (3.498). P/E Ratio (-1.088) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIR in upward trend: price rose above 50-day moving average on October 26, 2026
VIR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on VIR as a result. In 68 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for VIR just turned positive on October 27, 2026. Looking at past instances where VIR's MACD turned positive, the stock continued to rise in 32 of 41 cases over the following month. The odds of a continued upward trend are 78%.
The 10-day moving average for VIR crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 205 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 130 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for VIR moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 27 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
VIR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.498). P/E Ratio (-6.898) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NKTX | VIR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 37 Fair valued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 96 | |
PRICE GROWTH RATING 1..100 | 84 | 35 | |
P/E GROWTH RATING 1..100 | 14 | 81 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIR's Valuation (19) in the null industry is in the same range as NKTX (37). This means that VIR’s stock grew similarly to NKTX’s over the last 12 months.
VIR's Profit vs Risk Rating (100) in the null industry is in the same range as NKTX (100). This means that VIR’s stock grew similarly to NKTX’s over the last 12 months.
VIR's SMR Rating (96) in the null industry is in the same range as NKTX (97). This means that VIR’s stock grew similarly to NKTX’s over the last 12 months.
VIR's Price Growth Rating (35) in the null industry is somewhat better than the same rating for NKTX (84). This means that VIR’s stock grew somewhat faster than NKTX’s over the last 12 months.
NKTX's P/E Growth Rating (14) in the null industry is significantly better than the same rating for VIR (81). This means that NKTX’s stock grew significantly faster than VIR’s over the last 12 months.
| NKTX | VIR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| Momentum ODDS (%) | N/A | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 78% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 80% |
| Advances ODDS (%) | 8 days ago 84% | 3 days ago 76% |
| Declines ODDS (%) | 2 days ago 89% | 10 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NKTX’s FA Score shows that 1 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).
- NKTX’s FA Score: 1 green, 4 red.
- VIR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NKTX’s TA Score shows that 5 TA indicator(s) are bullish while VIR’s TA Score has 6 bullish TA indicator(s).
- NKTX’s TA Score: 5 bullish, 4 bearish.
- VIR’s TA Score: 6 bullish, 4 bearish.
Price Growth
NKTX (@Biotechnology) experienced а -11.76% price change this week, while VIR (@Biotechnology) price change was +17.20% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
NKTX is expected to report earnings on Mar 25, 2027.
VIR is expected to report earnings on Feb 25, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NKTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To NKTX | 1D Price Change % | ||
|---|---|---|---|---|
| NKTX | 100% | -15.09% | ||
| CRSP - NKTX | 49% Loosely correlated | -9.77% | ||
| EDIT - NKTX | 47% Loosely correlated | -8.91% | ||
| PROK - NKTX | 45% Loosely correlated | -3.48% | ||
| VIR - NKTX | 45% Loosely correlated | -3.63% | ||
| RNAC - NKTX | 45% Loosely correlated | -1.85% | ||
More | ||||
VIR and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIR has been loosely correlated with BEAM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if VIR jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To VIR | 1D Price Change % | ||
|---|---|---|---|---|
| VIR | 100% | -3.63% | ||
| BEAM - VIR | 54% Loosely correlated | -6.92% | ||
| EDIT - VIR | 54% Loosely correlated | -8.91% | ||
| DNLI - VIR | 52% Loosely correlated | -2.36% | ||
| SLDB - VIR | 52% Loosely correlated | +2.14% | ||
| BCYC - VIR | 51% Loosely correlated | -2.12% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ATTR | 96.21 | -0.01 | -0.01% |
| Arin Tactical Tail Risk ETF | |||
| FIDU | 89.61 | -0.12 | -0.13% |
| Fidelity MSCI Industrial Index ETF (FIDU) | |||
| FIDI | 28.75 | -0.13 | -0.45% |
| Fidelity International High Dividend ETF (FIDI) | |||
| HOMZ | 43.80 | -0.83 | -1.86% |
| Hoya Capital Housing ETF (HOMZ) | |||
| SOUX | 3.14 | -0.31 | -9.03% |
| Defiance Daily Target 2X Long SOUN ETF (SOUX) | |||